1. Events and Webinars
  2. Dermatology
  3. Product events and webinars
  4. Xolair® (omalizumab): on-demand webinars
  5. Challenges and pragmatic solutions in the management of chronic spontaneous urticaria (CSU)

Prescribing information

 

Challenges and pragmatic solutions in the management of chronic spontaneous urticaria (CSU)

General Practitioner Dr Vincent McGovern interviews allergy specialists Dr Chris Rutkowski and Alison Donnelly about the challenges they have faced when managing patients with CSU, and they share their experiences and learnings.

Video from a symposium event on 1 st October 2020 at The British Society of Allergy and Clinical Immunology (BSACI) annual digital conference.

 

*Post hoc analysis of phase 3 studies (ASTERIA I & II, and GLACIAL), demonstrated clinically meaningful improvements in quality of life (measured using DLQI) in patients with CSU.1

Indication:

Xolair is indicated as add on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment.2

References

  1. Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.
  2. Xolair® (omalizumab) 150 mg Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | December 2020 | 101350
Dermatology
Webinar
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]